FDA Lifts Clinical Hold on Intellia's MAGNITUDE-2 Phase 3 Trial for ATTRv-PN
NTLA has more than doubled off its 52-week low of $5.9.
Summary
Intellia Therapeutics announced that the FDA has lifted the clinical hold on its MAGNITUDE-2 Phase 3 trial for nexiguran ziclumeran (nex-z) in ATTRv-PN, allowing the company to resume patient enrollment and dosing.
Key Events · Product Development and Regulatory · NTLA
-
Clinical Hold Lifted for MAGNITUDE-2 Trial
The U.S. Food and Drug Administration (FDA) has removed the clinical hold on the Investigational New Drug (IND) application for the MAGNITUDE-2 Phase 3 clinical trial of nexiguran ziclumeran (nex-z) for patients with hereditary transthyretin amyloidosis with polyneuropathy (ATTRv-PN).
-
Trial Resumption and Enrollment Increase
Intellia plans to resume patient enrollment and dosing for the MAGNITUDE-2 trial. The target enrollment for the trial has been increased from approximately 50 patients to approximately 60 patients.
-
Study Modifications and Safety Measures
The company has aligned with the FDA on certain study modifications and mitigation measures, including enhanced safety monitoring of liver laboratory tests, following a previous observation of Grade 4 liver transaminases and increased total bilirubin in a patient.
-
Ongoing Engagement for MAGNITUDE Trial
FDA engagement is still ongoing regarding the clinical hold on the IND for the MAGNITUDE Phase 3 clinical trial of nex-z for patients with ATTR amyloidosis with cardiomyopathy (ATTR-CM), with an update expected once alignment is achieved.
Analysis · NTLA · Life Sciences
The FDA's decision to lift the clinical hold on the MAGNITUDE-2 Phase 3 trial for nexiguran ziclumeran (nex-z) is a significant positive development for Intellia Therapeutics. This allows the company to resume patient enrollment and dosing for a key pipeline asset targeting hereditary transthyretin amyloidosis with polyneuropathy (ATTRv-PN). While engagement with the FDA is ongoing for the related MAGNITUDE trial in ATTR-CM, the resolution for MAGNITUDE-2 removes a major regulatory hurdle and de-risks a portion of the nex-z program, potentially accelerating its path to market. The agreed-upon study modifications and enhanced safety monitoring demonstrate a clear path forward for this trial.
How filings like this one have moved
In the 30 days to Sep 14, 2026, 35.8% of the 1051 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.43%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, NTLA was trading at $16.10 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.6B. The 52-week trading range was $5.90 to $28.25. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.